Literature DB >> 9824505

Mouse lymphoblasts lose their immunogenicity and susceptibility to specific cytotoxic T lymphocyte lysis during maintenance in culture.

B Leshem1, D Brass.   

Abstract

This study was undertaken to search for possible mechanisms by which T-cell lines become non-immunogenic and refractory to cellular-mediated lysis during culture. We demonstrate that mouse lymphoblasts (LB) lost their susceptibility to specific cytotoxic T lymphocyte (CTL)-mediated lysis following culture for more than 5 days in the presence interleukin-2 (IL-2), IL-7 but not IL-4. In contrast, the cultured lymphoblasts (CLB) were efficiently lysed by specific antibody and C' and by CTL in the presence of concanavalin A. In addition, CLB did not inhibit cytotoxicity against LB in a cold target competition assay, indicating that CLB and LB differ in the expression of certain surface molecules. Indeed, a significantly lower expression of H-2D class I antigen, the Fas antigen and the adhesion molecules intracelluar adhesion molecule-1 (ICAM-1) and very late activation antigen-4 (VLA-4) was observed on the CLB surface. Consequently, CLB could not form conjugates with specific CTL, a prerequisite for CTL-mediated lysis. In addition, there was a marked decrease in CLB immunogenicity: the cultured cells were unable to stimulate allogeneic spleen cells in mixed lymphocyte culture nor could they induce a cytotoxic response following their injection into allogeneic mice. The reduced immunogenicity enabled the prolonged survival of active CLB in an allogeneic host. We suggest that the extended survival in an allogeneic tumour-bearing host of cultured, hence weakly immunogenic, anti-tumour CTL, will enable them the in vivo implementation of their anti-tumour activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9824505      PMCID: PMC1364408          DOI: 10.1046/j.1365-2567.1998.00611.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  53 in total

1.  Enumeration of lymphocyte-target cell conjugates by cytofluorometry.

Authors:  G Berke
Journal:  Eur J Immunol       Date:  1985-04       Impact factor: 5.532

Review 2.  Mechanism of lymphocyte-mediated cytotoxicity.

Authors:  P A Henkart
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

3.  Studies on the induction and expression of T cell-mediated immunity. X. Inhibition by Lyt 2,3 antisera of cytotoxic T lymphocyte-mediated antigen-specific and -nonspecific cytotoxicity: evidence for the blocking of the binding between T lymphocytes and target cells and not the post-binding cytolytic steps.

Authors:  J Fan; A Ahmed; B Bonavida
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

4.  Monoclonal antibody to a novel lymphocyte function-associated antigen (LFA-1): mechanism of blockade of T lymphocyte-mediated killing and effects on other T and B lymphocyte functions.

Authors:  D Davignon; E Martz; T Reynolds; K Kürzinger; T A Springer
Journal:  J Immunol       Date:  1981-08       Impact factor: 5.422

Review 5.  The in vitro generation of effector lymphocytes and their employment in tumor immunotherapy.

Authors:  E Kedar; D W Weiss
Journal:  Adv Cancer Res       Date:  1983       Impact factor: 6.242

Review 6.  Cytotoxic T-lymphocytes. How do they function?

Authors:  G Berke
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

7.  In vitro elicitation of cytotoxic response against a nonimmunogenic murine tumor by allosensitization.

Authors:  B Leshem; B Gotsman; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

8.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

Authors:  T R Mosmann; H Cherwinski; M W Bond; M A Giedlin; R L Coffman
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

9.  T lymphocyte-mediated cytolysis. III. Delineation of mechanisms whereby mitogenic and non-mitogenic lectins mediate lymphocyte-target interaction.

Authors:  G Berke; D Rosen; M Moscovitch
Journal:  Immunology       Date:  1983-08       Impact factor: 7.397

10.  The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.

Authors:  J H Donohue; M Rosenstein; A E Chang; M T Lotze; R J Robb; S A Rosenberg
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.